A microarray analysis in 2011 identified that glioma pathogenesis-related protein 1 (GLIPR1) was a methylation-silenced gene in the AML patients, and might serve as a marker to monitor the therapeutic effect of AML [25]. The gene discussed is GLIPR1; the disease is acute myeloid leukemia.